<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Biochem. Pharmacol.</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Biochemical pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0006-2952</issn><issn pub-type="epub">1873-2968</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6135671</article-id><article-id pub-id-type="pmcid-ver">PMC6135671.1</article-id><article-id pub-id-type="pmcaid">6135671</article-id><article-id pub-id-type="pmcaiid">6135671</article-id><article-id pub-id-type="manuscript-id">NIHMS976903</article-id><article-id pub-id-type="pmid">29935147</article-id><article-id pub-id-type="doi">10.1016/j.bcp.2018.06.010</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS976903</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA976903</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluating the Intestinal and Oral Absorption of the Prodrug Valacyclovir in Wildtype and huPepT1 Transgenic Mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Epling</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hu</surname><given-names initials="Y">Yongjun</given-names></name><xref ref-type="aff" rid="A1">a</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Smith</surname><given-names initials="DE">David E.</given-names></name><xref ref-type="aff" rid="A1">a</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib></contrib-group><aff id="A1">
<label>a</label>Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor MI, USA</aff><author-notes><corresp id="FN1"><label>*</label>Corresponding author at: University of Michigan, College of Pharmacy, 428 Church Street, Ann Arbor, MI 48109-1065, USA., Telephone: 734-647-1431, Facsimile: 734-615-6162, <email>smithb@umich.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p><bold>Conflict of interest</bold></p><p>The authors declare no conflicts of interest, financial or otherwise.</p></fn></author-notes><pub-date pub-type="epub"><day>21</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2018</year></pub-date><volume>155</volume><issue-id pub-id-type="pmc-issue-id">320429</issue-id><fpage>1</fpage><lpage>7</lpage><pub-history><event event-type="nihms-submitted"><date><day>21</day><month>06</month><year>2018</year></date></event><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>01</day><month>09</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-18 11:25:13.767"><day>18</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms976903.pdf"/><abstract id="Abs1"><p id="P1">The purpose of this work was to evaluate the intestinal permeability, oral absorption and disposition of the ester prodrug valacyclovir in wildtype mice and a huPepT1 transgenic mouse model. PepT1 (SLC15A1) is a transporter apically expressed along the lumen of the gastrointestinal tract and is responsible for the absorption of di-/tripeptides, ACE inhibitors, &#946;-lactam antibiotics and numerous prodrugs. Unfortunately, PepT1-mediated substrates that have been extensively studied were shown to exhibit species-dependent absorption and pharmacokinetics. Accordingly, in situ intestinal perfusion studies were conducted and valacyclovir uptake was shown to have a 30-fold lower K<sub>m</sub> and 100-fold lower V<sub>max</sub> in huPepT1 compared to wildtype mice. Moreover, inhibition studies demonstrated that the huPepT1 transporter alone was responsible for valacyclovir uptake, and segment-dependent studies reported significant reductions in permeability along the length of small intestine in huPepT1 mice. Subsequent oral administration studies revealed that the in vivo rate and extent of valacyclovir absorption were lower in huPepT1 mice, as indicated by 3-fold lower C<sub>max</sub> and 3-fold higher T<sub>max</sub> values, and an AUC<sub>0&#8211;180</sub> that was 80% of that observed in wildtype mice. However, no significant changes in drug disposition were observed between genotypes after intravenous bolus administration of acyclovir. Lastly, mass balance studies established that the bioavailability of acyclovir, after oral dosing of valacyclovir, was 77.5% in wildtype mice and 52.8% in huPepT1 mice, which corroborated values of 51.3% in clinical studies. Thus, it appears the huPepT1 transgenic mice may be a better model to study prodrug absorption and disposition in humans than wildtype mice.</p></abstract><abstract abstract-type="graphical" id="Abs2"><title>Graphical Abstract</title><p id="P2">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihms976903u1.jpg"/></p></abstract><kwd-group><kwd>Valacyclovir</kwd><kwd>Pharmacokinetics</kwd><kwd>huPepT1 Mice</kwd><kwd>Permeability</kwd><kwd>Absorption</kwd><kwd>Bioavailability</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>